Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

Open Access Highly Accessed Research article

Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial

Tran Ngoc Huu1*, Nguyen Trong Toan1, Ha Manh Tuan2, Ho Lu Viet2, Pham Le Thanh Binh2, Ta-Wen Yu3, Fakrudeen Shafi4, Ahsan Habib3 and Dorota Borys3

Author Affiliations

1 Pasteur Institute Ho Chi Minh City, 167 Pasteur Street District, 3 Ho Chi Minh City, Vietnam

2 Children’s Hospital 2, Ho Chi Minh City, Vietnam

3 GlaxoSmithKline Vaccines, 20 Avenue Fleming, 1300, Wavre, Belgium

4 GlaxoSmithKline Pharmaceuticals, 5 Embassy Links, SRT Road, 560 052, Bangalore, India

For all author emails, please log on.

BMC Infectious Diseases 2013, 13:95  doi:10.1186/1471-2334-13-95

Published: 21 February 2013

Abstract

Background

Pneumococcal infections are major causes of child mortality and morbidity worldwide and antibiotic resistance of Streptococcus pneumoniae is a major concern, especially in Asian countries. The present study was designed to evaluate the reactogenicity and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the licensed diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliovirus and H. influenzae type b vaccine (DTPa-HBV-IPV/Hib) in a 3-dose primary vaccination course in Vietnamese infants.

Methods

This phase III, open, randomised study was conducted in one centre in Ho Chi Minh City between February and July 2011. Healthy infants (N=300) were randomised (2:1) to receive either PHiD-CV co-administered with DTPa-HBV-IPV/Hib (PHiD-CV group) or DTPa-HBV-IPV/Hib alone (Control group) at 2, 3, and 4 months of age.

Results

Within 31 days post-vaccination, 8.2% of overall doses in the PHiD-CV group and 3.0% of overall doses in the Control group were followed by at least one solicited and/or unsolicited, local and/or general adverse event of grade 3 intensity. Pain at injection site was the most common grade 3 solicited symptom, which was reported following 6.5% and 1.0% of overall doses in the PHiD-CV and Control groups, respectively. Within 4 days post-vaccination, the most common solicited local and general symptoms reported with any intensity were pain (48.9% and 31.0% of doses in the PHiD-CV and Control groups) and irritability (58.0% and 40.4% of doses in the PHiD-CV and Control groups). Within 31 days post-vaccination, the incidence of unsolicited symptoms was comparable in both groups (following 12.3% and 14.8% of doses in the PHiD-CV and Control groups, respectively). Throughout the study, 13 serious adverse events (SAEs) were reported in 9 infants in the PHiD-CV group and 11 SAEs in 6 infants in the Control group. None of them were fatal or considered causally related to vaccination.

Conclusions

PHiD-CV had a clinically acceptable safety profile when co-administered with DTPa-HBV-IPV/Hib in Vietnamese infants. The reactogenicity of PHiD-CV was comparable to that observed in other South-East Asian populations.

Trial registration

ClinicalTrials.gov: http://NCT01153841 webcite

Keywords:
Pneumococcal conjugate vaccine; Infant immunisation; Safety; Reactogenicity; Vietnam; Co-administration